Human respiratory syncytial virus (HRSV) is a leading cause of severe acute lower respiratory tract infection in infants and children worldwide. Bovine RSV (BRSV) is closely related to HRSV and a significant cause of morbidity in young cattle. BRSV infection in calves displays many similarities to RSV infection in humans， including similar age dependency and disease pathogenesis. Polyanhydride nanoparticle-based vaccines (i.e.， nanovaccines) have shown promise as adjuvants and vaccine delivery vehicles due to their ability to promote enhanced immunogenicity through the route of administration， provide sustained antigen exposure， and induce both antibody- and cell-mediated immunity. Here， we developed ... More
Human respiratory syncytial virus (HRSV) is a leading cause of severe acute lower respiratory tract infection in infants and children worldwide. Bovine RSV (BRSV) is closely related to HRSV and a significant cause of morbidity in young cattle. BRSV infection in calves displays many similarities to RSV infection in humans， including similar age dependency and disease pathogenesis. Polyanhydride nanoparticle-based vaccines (i.e.， nanovaccines) have shown promise as adjuvants and vaccine delivery vehicles due to their ability to promote enhanced immunogenicity through the route of administration， provide sustained antigen exposure， and induce both antibody- and cell-mediated immunity. Here， we developed a novel， mucosal nanovaccine that encapsulates the post-fusion F and G glycoproteins from BRSV into polyanhydride nanoparticles and determined the efficacy of the vaccine against RSV infection using a neonatal calf model. Calves receiving the BRSV-F/G nanovaccine exhibited reduced pathology in the lungs， reduced viral burden， and decreased virus shedding compared to unvaccinated control calves， which correlated with BRSV-specific immune responses in the respiratory tract and peripheral blood. Our results indicate that the BRSV-F/G nanovaccine is highly immunogenic and， with optimization， has the potential to significantly reduce the disease burden associated with RSV infection in both humans and animals.
